Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-04-17 am EDT			5-day change	1st Jan Change
260.40 ^DKK	+1.24%		+8.21%	-19.94%

Apr. 17	Health Care Up Ahead of Earnings - Health Care Roundup	DJ
Apr. 17	Kailera makes a splash on Nasdaq as anti-obesity drug frenzy continues

Berenberg lowers price target for Novo Nordisk to 300 Danish kroner (360), reiterates buy - BN

Published on 03/12/2026 at 02:44 am EDT

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+1.24%

Berenberg lowers price target for Novo Nordisk to 300 Danish kroner (360), reiterates buy - BN

Latest news about Novo Nordisk A/S

Apr. 17	Health Care Up Ahead of Earnings - Health Care Roundup	DJ
Apr. 17	Kailera makes a splash on Nasdaq as anti-obesity drug frenzy continues
Apr. 17	Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up	RE
Apr. 17	Lilly CEO sees weight-loss drugs reaching about half of potential users at peak	RE
Apr. 17	Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds	RE
Apr. 17	Lilly's obesity pill draws 1,390 US prescriptions in launch week	RE
Apr. 17	Whistling Past Hormuz
Apr. 17	Lilly's Foundayo hits 1,390 prescriptions in debut week	RE
Apr. 17	Buy the Dip
Apr. 17	BNP Paribas cuts Novo Nordisk price target to DKK 295 (302), reiterates Neutral - BN	FW
Apr. 17	Citigroup trims Novo Nordisk price target to DKK 275 (309), reiterates Neutral - BN	FW
Apr. 16	Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds	RE
Apr. 16	Gerresheimer rebounds sharply on lender support	DP
Apr. 16	Lilly says Foundayo pill lowers heart attack, stroke risk in study	RE
Apr. 16	Novo Nordisk ramps up hiring following major workforce reductions	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

May. 06 - Earnings release - Q1 2026

More about the company